1315 Capital Acquires Aluris Sciences
The carved-out business provides contract manufacturing for life sciences, diagnostics and combination drug products.
1315 Capital acquired Aluris Sciences, a contract manufacturing organization offering formulation, filling, kitting, lyophilization, assembly, packaging, and supply chain services to life sciences, diagnostics, and combination drug product customers. The business was carved out from Argonaut Manufacturing Services' Life Sciences and Diagnostics division and will operate independently with support from Philadelphia-based healthcare-focused investor 1315 Capital.
Aluris serves customers from pilot-stage programs through clinical, validation, and commercial production.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.